dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

National survey on shortages of medicines and vaccines

Sotsiaalministeerium · 29. mai 2018
Viit
1.4-5/1840-1
Registreeritud
29. mai 2018
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-5 Rahvusvahelistele organisatsioonidele saadetavad aruanded ja küsimustikud (sotsiaalharta, sotsiaalkindlustuskoodeksi jm aruanded) (Arhiiviväärtuslik)
Toimik
1.4-5/2018
Vastutaja
Maris Jesse (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond)
Lahendamise tähtaeg
25. juuni 2018

Failid

  • 📎_WHO HQ National questionnaire_Final April 2018 EST.pdf550 KB
  • 📎_WHO HQ National questionnaire_Final April 2018.pdf524 KB
  • 📎EST.pdf81 KB

Sisu (failidest)

NATIONAL MEDICINE AND VACCINE SHORTAGES QUESTIONNAIRE Background: Shortages of medicines and vaccines is a complex global problem, with documented supply failure of medicines and vaccines being reported in countries at all levels of development, across every region of the world. In response to World Health Assembly (WHA) resolution WHA69.25, “Addressing the Global Shortage of Medicines and Vaccines”, the World Health Organization (WHO) is gathering information to assess the magnitude and nature of the problem of medicine and vaccine shortages and to identify strategies that are likely to improve the current situation. The focus of this investigation is medicine and vaccine supply side shortages. Objectives: The aim of this questionnaire is to gain a more comprehensive understanding of strategies used by countries to mitigate the risk of shortages and to assess to what extent shortages impact delivery of optimal health care to patients. Notes:  Please complete the questionnaire by indicating your answers to the best of your knowledge.  If supporting documents are available (e.g. legislations), kindly send them together with the questionnaire or indicate where the document can be found (e.g. web link).  After completing the questionnaire, please send directly to Tifenn Humbert, Technical Officer, Health Technologies and Pharmaceuticals Programme, DSP, WHO EURO at [email protected] ; and CC [email protected]; [email protected] and [email protected] no later than 25 June 2018. Name of Country: Estonia Name of Organization: State Agency of Medicines Name of contact person: Klara Saar Title of contact person: Ms Email address of contact person: Date: 06.06.2018 [email protected] 1. NOTIFICATION ABOUT SHORTAGES OR POTENTIAL SHORTAGES Is there a national mechanism for market authorization holders (or others) to notify the country authority(ies) in case of likely disruption of supply of medicines and vaccines? ☒ Yes  No  Not known Is reporting a shortage to the responsible authority(ies)  Voluntary  Not known voluntary or mandatory for market authorization holders? ☒ Mandatory Which national authority(ies) are responsible for implementation and/or enforcement of this requirement (e.g. State Agency of Medicines the NMRA, the national medical store etc.)? In Estonia marketing authorization holders are obliged to report a Please estimate how many times the entities indicated in the shortage. 127 shortages were reported in 2016 and 112 shortages in list to the right reported shortages to the responsible 2017. The reports were made by marketing authorization holders or their authority(ies) over the last 12 and 24 months? authorized representatives, however, some of them have also an activity license for wholesale distribution and/or manufacture of medicinal products. If Do reporting mechanisms request information on estimated ☒ Yes  No  Not Known yes: duration of the shortage If yes ☒ Start date; ☒ End date; ☒ Duration (weeks, months etc.) Do reporting mechanisms request the entities to provide ☒ Yes  Not known relevant authority(ies) with status updates including resolution of shortage?  No Are entities required to give advance notice of expected shortages or only report at the start of a shortage? A shortage must be reported at least 2 months in advance, except in If the former, please indicate the minimum amount of time exceptional circumstances. before the anticipated shortage that entities are required to report (e.g. at least 3 months before anticipated shortage) Do reporting mechanisms request information on causes of the ☒ Yes  Not known shortage (e.g. manufacturing, demand changes etc.)?  No ☒ Yes  Not known If a global notification system existed, would your country  No consider using such a system? If no, please explain. [If no, please explain why (e.g. competing priorities, legislative constraints etc.] In all ☒ Identification of medicine/vaccine (INN, Tradename, Dosage form, cases Strength, Name of manufacturer/supplier, manufacturing site, ATC code) If you had access to a global notification system, please ☒ Shortage status (Start date of shortage, Resolution date if known) indicate from the list to the right which information you would ☒ Reason for shortage find most useful?  Resolution strategy/plan  Alternate strength or presentation available ☒ Information on alternative sources available How likely is it that the information listed above could be  Very likely ☒ Likely  Not likely  Not known contributed by your country to a global notification system. 2. MEDICINE AND VACCINE WATCH LIST Is there a national watch list (such as a national list of Vital, Essential and Non-essential medicines and vaccines (VEN)) that a national authority actively monitors for availability?  Yes ☒ No State Agency of Medicines has made an overview of the medicinal products marketed in Estonia which do not have any alternatives available (no other medicinal products containing the same active Could you please attach a copy of the current list. substance in same dosage strength or dosage form). This list has been sent to marketing authorization holders and wholesalers for awareness and careful planning of manufacture and distribution. If  Yes  Not known Is this list used to determine which medicines’ and vaccines’ yes:  No shortage should be reported to the authorities? [If no, please indicate the criteria used to decide which medicines’ and vaccines’ shortages should be reported on.] 3. RESPONSE TO SHORTAGES Is action taken by the authorities or other actors once notified about a shortage or potential shortage? ☒ Yes  No ☒ Yes  Not known  No Are there policies and procedures that describe actions that authorities are expected or able to take when notified of State Agency of Medicines has developed an in-house standard different types of shortages? operation procedure for managing shortage reports. The procedure is specified in the State Agency of Medicines’ Job Description of the senior inspector. An in-house form is filled with the shortage information. A shortage notification containing product information, expected shortage duration, available alternatives and suggestion for patients to If contact doctor (if necessary) is published on the web page of State What actions are most frequently taken by authorities in yes: Agency of medicines. responding to a reported shortage? If applicable, the MAH will be contacted and asked about the possibility to distribute the medicinal product in another European Economic Area language packaging. An export restriction is considered. Does legislation(s) or any other provision(s) exist to support special or flexible procedures to authorize or register medicines and vaccines that have gone into shortage? (e.g. for Yes, a labelling exemption is possible. a medicine in shortage, an emergency or limited authorization http://www.ravimiamet.ee/en/exemptions-labelling-and-package-leaflet- may be given to an equivalent product, but with flexibilities on obligations-estonia normal labeling requirements) 4. COMMUNICATION OF SHORTAGES Is information about shortages communicated to healthcare providers, program managers, consumers and/or other key stakeholders? ☒ Yes  No State Agency of Medicines publishes the notifications of shortages on the Does the national authority communicate information on agency’s web page. These notifications are also available through the shortages to all relevant stakeholders, or is information RSS feed to all subscribers. disseminated through channels (e.g., state or district If necessary, the physicians and professional organizations of doctors authorities)? will be additionally notified by the State Agency of Medicines or by the marketing authorization holders. What are the mechanisms and the frequency of communication? If A notification is published on the web page of State Agency of Medicines (e.g. letters sent after each shortage report or information yes: after every shortage report. uploaded on website once a month) The biggest problem is to receive sufficient information about the shortage from the marketing authorization holders. Also, majority of the What are the key challenges in communicating information to shortages are reported less than 2 months in advance. This is often too health care providers, program managers, consumers and other short time to find alternative measures and provide continuous supply of key stakeholders? the medicinal product for the patients. A common reason for shortages is inaccurate planning of manufacture or distribution. 5. IMPACT OF SHORTAGES In your opinion do shortages of medicines and vaccines in your country pose a significant public health problem? ☒ Yes  No If Have there been any recent national or subnational reports on There are no such reports; however, managing shortages is a problem yes: shortages? If so, please attach a copy. for healthcare professionals. Antibiotics ☒ Severe  Moderate  Manageable Other anti-infectives  Severe ☒ Moderate  Manageable Oncology medication ☒ Severe  Moderate  Manageable Based on information available to you, including informal Emergency medication ☒ Severe  Moderate  Manageable information, which of the following levels of severity best Mental health medication  Severe ☒ Moderate  Manageable describes the impact that shortages of medicines and vaccines Cardiovascular medication  Severe ☒ Moderate  Manageable have in the delivery of healthcare in your country. Anesthetic medication  Severe ☒ Moderate  Manageable Vaccines ☒ Severe  Moderate  Manageable Other [please name]  Severe  Moderate  Manageable …………………………………………………………………………………………………… Sterile injectables  Severe ☒ Moderate  Manageable In your opinion, has the incidence of shortages of essential ☒ Increased  No opinion In all medicines and vaccines in your country increased, decreased or  Decreased cases: remained the same over the last 12 months?  No change Thank you for taking the time to complete this questionnaire. NATIONAL MEDICINE AND VACCINE SHORTAGES QUESTIONNAIRE Background: Shortages of medicines and vaccines is a complex global problem, with documented supply failure of medicines and vaccines being reported in countries at all levels of development, across every region of the world. In response to World Health Assembly (WHA) resolution WHA69.25, “Addressing the Global Shortage of Medicines and Vaccines”, the World Health Organization (WHO) is gathering information to assess the magnitude and nature of the problem of medicine and vaccine shortages and to identify strategies that are likely to improve the current situation. The focus of this investigation is medicine and vaccine supply side shortages. Objectives: The aim of this questionnaire is to gain a more comprehensive understanding of strategies used by countries to mitigate the risk of shortages and to assess to what extent shortages impact delivery of optimal health care to patients. Notes:  Please complete the questionnaire by indicating your answers to the best of your knowledge.  If supporting documents are available (e.g. legislations), kindly send them together with the questionnaire or indicate where the document can be found (e.g. web link).  After completing the questionnaire, please send directly to Tifenn Humbert, Technical Officer, Health Technologies and Pharmaceuticals Programme, DSP, WHO EURO at [email protected] ; and CC [email protected]; [email protected] and [email protected] no later than 25 June 2018. Name of Country: Name of Organization: Name of contact person: Title of contact person: Email address of contact person: Date: 1. NOTIFICATION ABOUT SHORTAGES OR POTENTIAL SHORTAGES Is there a national mechanism for market authorization holders (or others) to notify the country authority(ies) in case of likely disruption of supply of medicines and vaccines?  Yes  No  Not known Is reporting a shortage to the responsible authority(ies)  Voluntary  Not known voluntary or mandatory for market authorization holders?  Mandatory Which national authority(ies) are responsible for [Please name all national entities responsible for implementation and/or implementation and/or enforcement of this requirement (e.g. enforcement of requirement of reporting of shortages] the NMRA, the national medical store etc.)? Overseas manufacturers [Please indicate number of reports] Please estimate how many times the entities indicated in the Local manufacturers [Please indicate number of reports] list to the right reported shortages to the responsible Importers [Please indicate number of reports] authority(ies) over the last 12 and 24 months? Wholesalers [Please indicate number of reports] Retailers [Please indicate number of reports] Others [Please name and indicate number of reports] If yes: Do reporting mechanisms request information on estimated  Yes  No  Not Known duration of the shortage If yes  Start date;  End date;  Duration (weeks, months etc.) Do reporting mechanisms request the entities to provide  Yes  Not known relevant authority(ies) with status updates including resolution of shortage?  No Are entities required to give advance notice of expected shortages or only report at the start of a shortage? [Please indicate if reports need to be made in advance of a shortage or at the time of a shortage. If in advance of a shortage please indicate If the former, please indicate the minimum amount of time minimum time requirement specifying if there are different reporting before the anticipated shortage that entities are required to time requirements for different medicines and vaccines] report (e.g. at least 3 months before anticipated shortage) Do reporting mechanisms request information on causes of the  Yes  Not known shortage (e.g. manufacturing, demand changes etc.)?  No  Yes  Not known If a global notification system existed, would your country  No consider using such a system? If no, please explain. [If no, please explain why (e.g. competing priorities, legislative constraints etc.]  Identification of medicine/vaccine (INN, Tradename, Dosage form, In all Strength, Name of manufacturer/supplier, manufacturing site, ATC code) cases  Shortage status (Start date of shortage, Resolution date if known) If you had access to a global notification system, please indicate from the list to the right which information you would  Reason for shortage find most useful?  Resolution strategy/plan  Alternate strength or presentation available  Information on alternative sources available How likely is it that the information listed above could be  Very likely  Likely  Not likely  Not known contributed by your country to a global notification system. 2. MEDICINE AND VACCINE WATCH LIST Is there a national watch list (such as a national list of Vital, Essential and Non-essential medicines and vaccines (VEN)) that a national authority actively monitors for availability?  Yes  No Could you please attach a copy of the current list. [Please attach document or web link] If  Yes  Not known Is this list used to determine which medicines’ and vaccines’ yes:  No shortage should be reported to the authorities? [If no, please indicate the criteria used to decide which medicines’ and vaccines’ shortages should be reported on.] 3. RESPONSE TO SHORTAGES Is action taken by the authorities or other actors once notified about a shortage or potential shortage?  Yes  No  Yes  Not known Are there policies and procedures that describe actions that  No authorities are expected or able to take when notified of [If no, please describe how authorities decide on action in response to different types of shortages? shortages. If yes, kindly attach any key documents or web links] What actions are most frequently taken by authorities in [Please list the most frequent actions that the authorities take in If responding to a reported shortage? responding to reported shortages] yes: Does legislation(s) or any other provision(s) exist to support special or flexible procedures to authorize or register medicines and vaccines that have gone into shortage? (e.g. for [Please indicate whether such legislation or provision exists and if so a medicine in shortage, an emergency or limited authorization kindly attach a copy or provide a web link] may be given to an equivalent product, but with flexibilities on normal labeling requirements) 4. COMMUNICATION OF SHORTAGES Is information about shortages communicated to healthcare providers, program managers, consumers and/or other key stakeholders?  Yes  No Does the national authority communicate information on [Please describe if all key stakeholders are notified of all shortages by shortages to all relevant stakeholders, or is information the national authority(ies) or is there a cascading communication disseminated through channels (e.g., state or district strategy] authorities)? If What are the mechanisms and the frequency of communication? [Please indicate the mechanism by which different stakeholders are yes: (e.g. letters sent after each shortage report or information notified and whether this is routine action or only in special cases] uploaded on website once a month) What are the key challenges in communicating information to [Please describe the main challenges in communicating information to health care providers, program managers, consumers and other different stakeholders both in regards to level of information and key stakeholders? mechanisms of communication] 5. IMPACT OF SHORTAGES In your opinion do shortages of medicines and vaccines in your country pose a significant public health problem?  Yes  No [please indicate if any such reports have been produced by the NMRA, Have there been any recent national or subnational reports on NGOs, development partners or industry and if so kindly suggest how we shortages? If so, please attach a copy. may be able to obtain a copy] Antibiotics  Severe  Moderate  Manageable Other anti-infectives  Severe  Moderate  Manageable Oncology medication  Severe  Moderate  Manageable If Based on information available to you, including informal Emergency medication  Severe  Moderate  Manageable yes: information, which of the following levels of severity best Mental health medication  Severe  Moderate  Manageable describes the impact that shortages of medicines and vaccines Cardiovascular medication  Severe  Moderate  Manageable have in the delivery of healthcare in your country. Anesthetic medication  Severe  Moderate  Manageable Vaccines  Severe  Moderate  Manageable Other [please name]  Severe  Moderate  Manageable …………………………………………………………………………………………………… Sterile injectables  Severe  Moderate  Manageable In your opinion, has the incidence of shortages of essential  Increased  No opinion In all medicines and vaccines in your country increased, decreased or  Decreased cases: remained the same over the last 12 months?  No change Thank you for taking the time to complete this questionnaire.
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel